5.760USD+3.60%Mkt Cap: 65.42M USDP/E: —Last update: 2026-05-26
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap65.42M USD
Enterprise Value-52.53M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)-45.35M USD
Revenue/Share0.0000 USD
Last Price5.760 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.39
PEG—
EV/EBITDA0.97
EV/Revenue—
P/SInfinity
P/B0.46
EPS (TTM)-4.78
EPS (Forward)-3.98
52W Range
3.94013% of range18.00
52W High18.00 USD
52W Low3.940 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-5668.63%
ROE-34.06%
ROA-29.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-47.84M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-41.68%
Net Debt-114.79M USD
Net Debt/EBITDA2.12
Balance Sheet
Debt/Equity0.02
Current Ratio18.39
Quick Ratio17.67
Book Value/Sh11.91 USD
Cash/Share10.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 28, 2025
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)24.00 USD
Target Range24.00 USD – 24.00 USD
# Analysts1
Ownership
Shares Out.11.28M
Float5.80M
Insiders14.96%
Institutions55.47%
Short Interest
Short Ratio0.5d
Short % Float4.24%
Short % Out.4.17%
Shares Short470.34K
Short (prev mo.)387.03K
Technical
SMA 505.578 (+3.3%)
SMA 2007.575 (-24.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)78.08K
Avg Vol (10d)51.91K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—